TeraRecon and GLEAMER Partner on Clinical AI Platform
Several of Gleamer’s digital products will be incorporated into the ConcertAI platform.
A new partnership will allow ConcertAI to add bone fracture and pulmonary nodule technology to its AI-powered platform.
TeraRecon, part of ConcertAI, is partnering with GLEAMER to bring these new features to the platform. GLEAMER will be providing access to three of its products: BoneView (FDA), BoneView (CE), and ChestView (CE), all of which use AI.
In a press release, TeraRecon president Dan McSweeney said, “We are thrilled to partner with GLEAMER and integrate their advanced AI algorithms into the Eureka Clinical AI platform. This collaboration perfectly aligns with our commitment to deliver cutting-edge solutions that revolutionize medical imaging and enhance patient outcomes."
GLEAMER’s BoneView is one of the first FDA-approved AI-powered technologies for detecting bone fractures.
Christian Allouche, CEO and co-founder of GLEAMER, also said in a press release, "It is inspiring to be part of this partnership and to offer tools that aim to assist busy radiographers, radiologists, and clinicians to manage patients at the point of care better, adding value for both staff and the patients."
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
